ArticleMedical oncology (Northwood, London, England)2013

Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Jing Gao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.